Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7407944B2 · kind B2 · utility
37Cited by
20References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 25, 2004 |
| Grant date | Aug 5, 2008 |
| Priority date | — |
| Expiry date | Jan 4, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55561
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.